The new Abilify Maintena (aripiprazole) will put more focus on avoiding mix-ups with intramuscular "atypical" antipsychotics

The new Abilify Maintena (aripiprazole) will put more focus on avoiding mix-ups with intramuscular "atypical" antipsychotics.

Abilify Maintena will be the THIRD long-acting injectable atypical antipsychotic on the market...and will join Invega Sustenna (paliperidone) and Risperdal Consta (risperidone).

These are alternatives to oral antipsychotics for patients with schizophrenia and other psychiatric disorders.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote